VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | The role of autologous transplantation in young and fit patients with multiple myeloma in 2022

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, comments on the role of autologous hematopoietic stem cell transplantation (autoHSCT) in the treatment of young and fit patients with multiple myeloma in the era of novel immunotherapeutic agents. Prof. Mohty argues that the Phase III DETERMINATION study (NCT01208662) confirmed the role of autoHSCT as a standard of care in this patient population. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter